Ayuvant
1 known investors
Find your way into Ayuvant
38 people in our graph share verified history with the Ayuvant team — schools, employers, funds. One of them is your warm intro.
Laura Lentzunlockedknows Lucas Czentner · together at Universiteit Utrecht (overlapped)
×4knows the team · via Universidad de Buenos Aires
×7knows the team · via Universiteit Utrecht
Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.
Founders & leadership
LC
Lucas Czentnerin𝕏Co-Founder | CEOHe worked in immunotherapy development and commercialization at pharmaceutical companies and earned a Ph.D. in cancer immunotherapies from Utrecht University.
Investors · 1
Frequently asked questions
- What does Ayuvant do?
- Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.
- Who founded Ayuvant?
- Ayuvant was founded by Lucas Czentner.
- Who are Ayuvant's investors?
- Ayuvant's investors include AIR Capital.